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require a period of time after implantation prior to use.
Autogenous arteriovenous fistulas typically require a mat-
uration period of 6 weeks to 6 months before first cannu-
lation, whereas prosthetic grafts are not accessed for 2 to
4 weeks to permit tissue incorporation.1 For patients
requiring immediate dialysis, which is the largest growing
group of patients undergoing dialysis, neither autogenous
nor ePTFE prosthetic grafts are designed to be used in
these patients. Early cannulation with these two options
has a high risk of rapid thrombosis, infection, seroma,
weeping, hematoma, graft laceration, or bleeding into the
tunnel of the recently implanted grafts.
There have been reports in the literature supporting
the early cannulation after implantation of prosthetic vas-
cular access grafts.2-5 There are other graft products that
have been used for early cannulation in hemodialysis, but
these have not been proved to be successful with regard to
patency and complication rate.6,7 Most clinicians still favor
the placement of temporary central venous catheters
More than 220,000 patients undergo hemodialysis in
the United States annually at a predicted increase of 8%
per year. Typically, long-term access to the vascular system
is provided by an arteriovenous fistula or expanded poly-
tetrafluoroethylene (ePTFE) bridge graft. However, both
of these accesses have a common limitation in that they
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Objectives: The purpose of this study was to compare in a randomized, prospective, and controlled study, the perfor-
mance of a multilayered, self-sealing polyurethane vascular access graft (PVAG) and expanded polytetrafluoroethylene
(ePTFE) vascular access grafts in hemodialysis applications. Performance measures included graft survival, complica-
tions, time to early cannulation, and hemostasis times after cannulation.
Study Design: A total of 142 patients were randomized equally to receive one of the two grafts after meeting all eligi-
bility requirements. All patients were followed up prospectively to 12 months or to the end of secondary patency.
Specifically, this study documented the performance of the PVAG and ePTFE grafts by determining the patencies and
complications for both grafts.
Results: Patient characteristics between the two groups were similar with respect to risk factors and demographic char-
acteristics (P > .05). Life-table patencies from the date of first dialysis were primary patency: PVAG 55% versus ePTFE
47% (6 months) and PVAG 44% versus ePTFE 36% (12 months) and secondary patency: PVAG 87% versus ePTFE 90%
(6 months) and PVAG 78% versus ePTFE 80% (12 months). None of these differences were significant (P > .05). Both
primary and secondary patencies were also not significantly different when the date of implantation was the starting
point. Adverse events and complications were similar for the two groups, except the PVAG group had a higher inci-
dence of technical complications manifested by graft kinking when compared with the control cohort (P < .05).
Additionally, there was no significant difference in complication rates between these two groups with regard to infec-
tion and bleeding. When the time to hemostasis after cannulation was compared at 5
minutes or less, there were more PVAG cannulation sites that achieved hemostasis compared with ePTFE sites, and this
difference was significant (P < .0001). When time to first dialysis access was compared between the two grafts, 53.9%
of all PVAG grafts were cannulated before 9 days versus none with the ePTFE grafts (P < .001). However, long-term
graft survival was not significantly different when PVAG patients were stratified into early (< 9 days) and the late access
(9 ≥ days) groups (P = .29).
Conclusions: The PVAG graft allows for early access without compromising long-term performance. Both PVAG and
standard ePTFE grafts have similar long-term outcomes, despite early access with the PVAG vascular access grafts.
(J Vasc Surg 2001;34:465-73.)
(TVCs) to provide immediate access until the graft or fis-
tula matures.8
It is reported that approximately 250,000 temporary
and long-term hemodialysis catheters are inserted annually
in the United States.8 A prospective study has demon-
strated that 2.3 hemodialysis catheters per patient per year
are needed for the average patient undergoing dialysis,9
and Eggers10 has reported that the use of catheters for
dialysis remains high and that this is the most costly group
of patients according to the Medicare database. Use of
these catheters contributes to a significant amount of com-
plications including bacteremia,10,11 central vein stric-
tures,6 lower flow rates,12 increased mortality and
hospitalization rates,12-16 and decreased hemoglobin lev-
els.17 The placement of central venous catheters has also
been associated with increased subsequent risk of failure of
future access grafts placed in the veins ipsilateral to the site
of the TVC placement.8
Creation of a vascular access with early access for
hemodialysis and acceptable long-term performance con-
tinues to be an elusive goal. A new polyurethane vascular
access graft (PVAG) has been made with a new poly-
etherurethaneurea material (the Vectra graft manufactured
by Thoratec Laboratories Corporation in Pleasanton,
Calif). This new graft, designed to provide early access
without compromising long-term performance, has a solid
nonpermeable middle layer that allows the graft wall to
seal rapidly after a needle puncture and removal, enabling
the graft to be cannulated for dialysis within 24 hours after
implantation. The inner and outer layers of the graft are
porous. The inner layer is made of the proprietary product
Thoralon, which is impermeable. The polyurethaneurea
present in this graft differs from other polyurethanes by a
different covalent bonding that allows this material signif-
icant stability. This same polyurethaneurea is used as the
blood sac in ventricular-assist devices since the 1980s
without any evidence of material instability.
The objective of this article is to report the results of
a randomized, prospective, and controlled multicenter
clinical study comparing the PVAG graft with standard
ePTFE grafts for hemodialysis access. Specifically, this
study documented the long-term graft performance
(patency and complication rates) and the following dialy-
sis outcomes: time to first dialysis access and time to
hemostasis after needle removal.
METHODS
Between June 1998 and December 1999, 142 patients
requiring the implantation of a prosthetic graft for
hemodialysis were prospectively randomized to receive
either the PVAG or a standard nontapered ePTFE graft
(either Gore-Tex, Flagstaff, Ariz, or Impra, Tempe, Ariz)
in a straight or looped configuration. Randomization
occurred in blocks so that an equal number of subjects
would be assigned to each of the two treatment groups.
The randomization code was generated specifically for
each institution. Attempts were made to place grafts in
patients who had not undergone a previous prosthetic
implant for hemodialysis on the ipsilateral side. Veins
larger than 3.5 mm were used for the venous anastomosis
as determined preoperatively by vein mapping with a
tourniquet technique or intraoperatively with coronary
dilators. All grafts implanted were 6 mm in diameter. All
experimental grafts were implanted with a sheathed tun-
neler supplied by the manufacturer. Control grafts were
placed with either a Kelly-Wick tunneler or a sheathed
tunneler (Gore-Tex or Scanlan, St Paul, Minn).
Five institutions participated in this study, which was
conducted under an Investigational Device Exemption
protocol approved by the Food and Drug Administration.
Each center obtained approval by the Institutional Review
Board from its respective institution before participating in
this study. Enrollment of patients by each institution con-
sisted of Virginia Vascular Associates, Norfolk, Va, 55
patients (27 PVAG implants, 28 ePTFE implants); Yale-
New Haven Organ Transplant Center, New Haven, Conn,
5 patients (3 PVAG implants, 2 ePTFE implants); Ochsner
Clinic, New Orleans, La, 17 patients (11 PVAG implants,
6 ePTFE implants); Bamberg Hospital, Bamberg, SC, 36
patients (17 PVAG implants, 19 ePTFE implants); and
Oregon Surgical Consultants, Portland, Ore, 29 patients
(13 PVAG implants, 16 ePTFE implants). Patient enroll-
ment was not predicated on the need of early cannulation
of the graft. However, information with regard to the need
of urgent dialysis was obtained. Criteria for urgent dialysis
involved electrolyte imbalance, uremia, and fluid overload.
Baseline data on etiology, risk factors, demographics, and
prior dialysis shunt placement were obtained before
implantation. Intraoperative data were obtained from the
implanting surgeon by forms and from operative notes.
Postoperative follow-up information was obtained on all
patients either through review of the dialysis sheets from
the dialysis units or by forms from each center. All patients
were followed up for 12 months or until the patient was
discontinued from the study before 12 months. The fol-
lowing key definitions were used in the analysis: Early
Puncture/Access: use of the prosthetic graft before 9 days
after implantation; Early Complication: complication that
occurs equal to or within 30 days of implantation; and First
Use/First Access Date: date the prosthetic graft was first
punctured for dialysis access at any facility.
All data were entered into an MS Access database
(Microsoft Redmond, Wash) and analyzed with the
Statistic Analysis Software (SAS Release 6.12; SAS, Inc,
Cary, NC). Definitions for all outcome parameters were
taken from reporting standards for vascular grafts.18
Survival analyses were conducted with the Kaplan-Meier
product limit estimator and the log-rank test. The fre-
quency of adverse events, complications, and deaths was
tabulated by event and compared between treatment
groups by event timing between early events (< 30 days),
late events (> 30 days), and total events. Patencies and
complication rates were determined from the date of
implantation and also from the date of first dialysis access
with the graft, primarily because of a significant number of
PVAG grafts cannulated for early access.
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RESULTS
Patient characteristics between the two groups (Tables
I and II) were similar with respect to risk factors and
demographic characteristics (P > .05). Previous vascular
shunts and placement of TVCs were also comparable
between the two groups (P > .05).
The implantation procedure parameters (Table III)
were also similar for both groups except for the graft
placement location. There were a higher number of PVAG
patients with an upper arm (63.4%) graft, and there were
a higher number of control patients with a forearm graft
(63.4%). This difference was statistically significant (P <
.001). Subgroup analysis of patency rates of the grafts was
stratified by graft location because there was a higher inci-
dence of upper arm grafts in the PVAG group. There was
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no significant difference in patency rates in all groups
determined by location of graft placement (Table IV). In
addition, patients randomized to PVAG grafts had a
slightly higher number of lesions/plaques identified in the
native arterial vessel at the time of implantation (PVAG, 8
patients; ePTFE, 3 patients).
Forty-nine patients in this study were identified as
requiring urgent or emergency dialysis. Factors that were
identified include hyperkalemia, uremia, and evidence of
fluid overload. Before randomization into the study, 29
patients underwent placement of TVCs for dialysis.
Thirteen of the remaining patients randomized to the
PVAG group did not undergo placement of a TVC,
whereas all seven of the patients randomized to the ePTFE
group underwent TVC placement. Randomization of
early use of the grafts was not part of this trial. The inves-
Table I. Patient demographics
Characteristic PVAG (n = 71) ePTFE (n = 71) P value
Sex .24
Male 27 (38.0%) 35 (49.3%)
Female 44 (62.0%) 36 (50.7%)
Age (mean, SD) y 60.1 (12.7) 56.2 (14.0) .08
Height (mean, SD) cm 167.1 (10.7) 168.9 (11.9) .36
Weight (mean, SD) kg 80.3 (22.3) 82.4 (24.1) .60
Race (frequency) %
White 32 (45.1) 25 (35.2) .20
Black 38 (53.5) 41 (57.7)
Other 0 (0.0) 5 (7.1)
Unknown 1 (1.4) 0 (0.0)
No prior hemodialysis (frequency, %) 36 (50.7) 38 (53.5) .87
Previous dialysis shunt 35 (49.3) 33 (46.5) .87
Previous peritoneal dialysis 9 (12.7) 7 (9.9) .79
Recent temporary venous catheter (< 30 d) 33 (46.5) 29 (40.9) .61
Table II. Origin of conditions that requiring long-term dialysis
PVAG (n = 71) ePTFE (n = 71)
Origin No. % No. % P value
Diabetes mellitus 44 62.0 45 63.4 .44
Hypertensive nephrosclerosis 17 23.9 24 33.8 .27
Chronic glomerulonephritis 3 4.2 4 5.6 1.00
Polycystic disease 3 4.2 2 2.8 1.00
Interstitial nephritis 2 2.8 0 0.0 .48
Chronic pyelonephritis 2 2.8 0 0.0 .48
Hypertension
Mild 2 2.9 7 10.4 .26
Moderate 21 30.9 24 35.8
Severe 2 2.9 2 3.0
Controlled 43 63.2 34 44.2
Not reported 3 4.2 4 5.6
Tobacco use 12 16.9 10 14.1 .82
Hyperlipidemia 13 18.3 18 25.4 .42
Obesity 23 32.4 26 36.6 .42
Hypercoagulation 1 1.4 2 2.8 1.00
Other 31 43.7 34 47.9 .74
Unknown 7 9.9 2 2.8 NA
tigators chose to use the PVAG graft early because of its
design features and accessed the ePTFE graft according to
standard treatment.
Of the 142 patients who were enrolled in this study, 19
patients did not undergo dialysis with the implanted grafts
(8 PVAG and 11 ePTFE) for the following reasons: early
death (2 patients), renal function recovery (4 patients), lost
to follow-up (3 patients), graft failure (5 PVAG, 4 ePTFE
patients), and unrequired dialysis (1 patient). In addition,
there were 20 deaths (11 PVAG, 9 ePTFE grafts) during
the follow-up; none were associated with the grafts.
Primary and secondary patencies. Primary and sec-
ondary patency rates were determined with Kaplan-Meier
methods from the date of implant as the starting point for
determining patency rates (Figs 1 and 2). The data
demonstrated no significant difference in both primary
and secondary patency between the PVAG graft and
ePTFE graft. The primary patency was PVAG 51% versus
ePTFE 59% (6 months) and PVAG 44% versus ePTFE
43% (12 months) (P = .47). The secondary patency 
was PVAG 85% versus ePTFE 86% (6 months) and PVAG
74% versus ePTFE 79% (12 months) (P = .64). Both 
primary and secondary patencies were also not signifi-
cantly different when the date of first dialysis was the 
starting point. Because there were a significant number 
of PVAG patients who underwent dialysis earlier than
ePTFE patients, primary and secondary patencies were
determined for both grafts. The data demonstrate again
no significant difference in patency rates between the 
two groups.
Because a significant number of PVAG patients under-
went early cannulation, we performed a subgroup analysis
to determine patencies for patients with early access
(defined as cannulation before 9 days) and late access. Six-
month primary patencies were early access, 49%, and late
access, 59%. Secondary patencies were early access, 85%,
and late access, 97%.
Time to first dialysis access. A significant portion of
PVAG grafts were cannulated earlier (< 9 days) for dialysis
as compared with the ePTFE grafts (Table V). Twenty-one
of 63 PVAG grafts were cannulated within 3 days of
implant with 10 of those grafts being cannulated within 24
hours. Overall, the mean time to first use was significantly
(P < .006) shorter for PVAG grafts (19.8 ± 33.0 days)
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Table III. Implantation procedure details
Parameter PVAG (n = 71) ePTFE (n = 71)
Graft location (n, %)
Forearm 26 (36.6) 45 (63.4)
Upper arm 45 (63.4) 26 (36.6)
Graft positioning (n, %)
Loop
Forearm 26 (36.7) 43 (60.6) 
Upper arm 14 (19.7) 8 (11.3)
Straight
Forearm 0 (0.0) 2 (2.8)
Upper arm 31 (43.6) 18 (25.3)
Plaque/lesions present (n, %) 8 (11.3) 3 (4.2)
Intraoperative complications observed (n, %) 3 (4.2) 1 (1.3)
Hemostatic agents used (n, %) 3 (4.2) 4 (5.6)
Graft length, in situ (cm) mean (SD) 29.5 (6.7) 33.7 (7.2)
Implantation time, min (SD) 98.9 (39.6) 87.1 (36.3)
Table IV. Analysis of patency by graft location
Kaplan-Meier product limit survival estimator
6-month probability (SE)
Outcome Factor PVAG Control P value
Primary patency
Total 0.51 (0.06) 0.59 (0.06) .47
Forearm 0.44 (0.10) 0.57 (0.08) .54
Upper Arm 0.55 (0.08) 0.60 (0.11) .25
Secondary patency
Total 0.85 (0.04) 0.86 (0.04) .64
Forearm 0.88 (0.07) 0.83 (0.06) .79
Upper Arm 0.84 (0.06) 0.89 (0.07) .45
compared with grafts of control patients (41.2 ± 47.8
days). Control patients with and without prior graft history
had similar mean times to first use, 38 and 44 days, respec-
tively. However, PVAG patients with prior grafts had much
shorter times to first use (13.4 ± 17.5 days) than those
patients with no prior graft history (27.3 ± 44.0 days).
An overall difference in the two groups was the find-
ing that more than one half of the PVAG grafts were used
for dialysis within 8 days (one third within 3 days and 11
patients within 1 day) of implantation. No control grafts
were used within the first 8 days after implant. Indeed,
only four control grafts (6.7%) were used within the first 2
weeks of implant. In contrast, 43 PVAG grafts (68.3% of
all PVAG patients) were cannulated within 2 weeks of
implant.
Hemostasis after cannulation. The time required to
achieve hemostasis after needle removal for PVAG patients
was compared with that for ePTFE patients (Table VI). A
specific protocol was developed for each dialysis center to
determine bleeding time. Each center was blinded, and 15
gauge needles were used in all centers for cannulation.
Manual compression was performed in 2-minute incre-
ments to determine hemostasis of the grafts. A total of
1372 punctures among the PVAG subjects and 1256
punctures among the ePTFE subjects were analyzed. The
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mean hemostatic time to sealing for the PVAG patients
was 3.5 minutes, and for the ePTFE patients it was 7.4
minutes. The difference was significant (P < .0001).
Approximately one half of all punctures of PVAG grafts
took 2 minutes or less to reach hemostasis, whereas few
control graft punctures reached hemostasis by 2 minutes.
When the time to reach hemostasis was compared at 5
minutes or less, 80.7% of the arterial punctures and 85.2%
of the venous punctures achieved hemostasis within 5
minutes with the PVAG graft. However, only 26.8% and
31.9% of the arterial and venous punctures achieved
hemostasis within the same time interval with the ePTFE
grafts (P < .0001).
Adverse events. Adverse events were categorized into
major (requiring surgical or percutaneous interventions)
and minor (not requiring operative intervention). Minor
complications included suspected graft infection treated
by antibiotics, wound healing/skin erosion, and diagnos-
tic procedures that did not result in an operative interven-
tion. The rate of these complications, including events
that occurred within 30 days of implant and late events (>
30 days after implant), were similar between the two treat-
ment groups (16 PVAG and 16 ePTFE).
All major complications during patient follow-up were
grouped into general events (infection, anastomotic
Fig 1. Survival from implant to end of primary patency. Circles,
ePTFE; lines, Vectra.
Fig 2. Survival from implant to end of secondary patency. Circles,
ePTFE; lines, Vectra.
Table V. Percent of grafts versus time to first cannula-
tion (%)
PVAG ePTFE
Characteristic (n = 71) (n = 71)
Grafts accessed within 
3 d 33.3 0
8 d* 53.9 0
14 d 68.2 6.7
*P < .001 for test of 0 to 8 versus 9+ days by study group.
Table VI. Time to hemostasis after dialysis needle removal
PVAG ePTFE
Characteristic (n = 71)* (n = 71)†
Time to hemostasis 
≤ 2 min Arterial—45.2% Arterial—12.6%
Venous—53.5% Venous—13.3%
≤ 5 min Arterial—80.7% Arterial—26.8%
Venous—85.2% Venous—31.9%
*N = 1372 punctures.
†N = 1256 punctures.
obstruction or thrombosis, pseudoaneurysm, kinking,
stenosis, wound healing), native vessel disease, patient
related factors, technical factors, and deaths (Table VII).
The total number of complications within these groups
was not statistically different between the PVAG and
ePTFE grafts (P > .05), except for native vessel disease and
kinking. There were a total of 10 kinking-related events (9
patients) with PVAG grafts during this study. Of these, one
event was not graft related, and three events were due to
technical factors attributed to the implantation procedures
specific to the PVAG graft (placement of the graft superfi-
cially relative to the deep native vein, revision modifica-
tion, and a kink at a banding suture after attempted
plication). The other six kinking events were identified
postoperatively during revision procedures and were asso-
ciated with the graft-handling properties. This graft tends
to axially elongate over time, and this must be accommo-
dated with changes in surgical technique. All six of these
events were successfully resolved with thrombectomy (1
patient), angioplasty (1 patient), angioplasty with stent
placement (1 patient), and surgical revision (3 patients).
Regarding complications due to inflow and outflow
native vessel disease, the PVAG patients had a higher num-
ber of events as compared with ePTFE patients. These
events were investigated and further categorized accord-
ing to arterial disease, graft placement (virginal arm, no
history of access placement, or nonvirginal arm, previous
implantation of ePTFE graft fistula), and preexisting
patient related conditions as shown in Table VII. There
was a higher incidence of nonvirginal arm graft placement
in the PVAG group and a higher incidence of preexisting
patient factors that may have predisposed that group to
native vessel disease.
DISCUSSION
Even though early cannulation of prosthetic vascular
grafts has been proposed in published literature, it is not a
commonly accepted practice. In fact, the Dialysis
Outcomes Quality Initiative (DOQI) guideline for
hemodialysis access is 21 days after implantation before
cannulation. It is well-known that the process of cannula-
tion itself is a risk factor that contributes to the false
aneurysms, seroma, hematoma and thrombosis. However,
in this study, the long-term performance (patency and
complication rates) appears to be unaffected by the early
cannulation of the PVAG graft. As can be seen from the
Tables VI and VII, early cannulation did not adversely
affect the long-term patency rates.
There have been several reports in the literature describ-
ing early cannulation of ePTFE graft for hemodialysis.
Hakaim and Scott4 and Tordoir et al19 reported their experi-
ence with early cannulation of stretch ePTFE graft (Gore-
Tex). Both groups reported acceptable rates of complication
and patency when the grafts were placed in a tight tunnel cre-
ated with a Kelly-Wick type tunneler (Impra, Tempe, Ariz).
Their recommendation was that early cannulation of stretch
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Table VII. Major complications during the study (all patients)
PVAG ePTFE
Complication No. of events No. of patients No. of events No. of patients
General events
Anastomotic obstruction 39 22 29 20
Aneurysm 0 0 2 2
Infection, surgical 4 4 4 4
Intragraft obstruction 10 9 16 14
Kinking 6 6 0 0
Pseudoaneurysm 0 0 1 1
Wound healing/skin erosion 2 2 0 0
Subtotal complications* 61 32 52 31
Native vessel disease
Arterial disease 6 6 2 2
Central and distal vein disease
Nonvirginal arm related† 10 8 3 2
Virginal arm incidents
Preexisting conditions‡ 24 11§ 8 7
No reported conditions 10 7 5 5
Patient events|| 8 7 2 2
Deaths 11 11 9 9
Technical events¶ 18 13 8 7
*Patient within category may have had more than one complication.
†Nonvirginal arm is defined as prior implantation of a PTFE graft or the multiple placements of fistulas (indicating multiple failed fistulas) in the same arm
as the study graft.
‡Stenotic disease indicated by prior history or diagnostic procedures, TVC placement in the same side as study graft or history of multiple TVC placements,
and history of multiple prior shunt failures.
§Five complicated patients experienced 16 events due to multiple underlying patient factors.
||Include edema, hypotension, hypercoagulable condition, and ecchymosis.
¶Include compression (external), hematoma, kinking due to technique, steal syndrome, laceration, and nerve release procedure.
ePTFE graft was acceptable without untoward results.
Sottiurai et al20 demonstrated 36 Gore-Tex PTFE grafts that
were accessed early with no adverse results when the diame-
ter of the tunneler matched the diameter of the graft.
With regard to location of graft placement, there were
more PVAG grafts placed in the upper arm as compared
with the ePTFE grafts, as seen in Table III. When the
patient groups were stratified according to the location of
graft placement, graft survival was not different for both
the forearm and upper arm locations.
There is some concern that early access of a graft
could lead to a decrease in graft survival. The PVAG sub-
jects were subdivided between those with early access (<9
days) and those with later access (>9 days) to determine
if early access compromised graft survival. The early use
of the graft did not adversely affect the loss of long-term
primary or secondary patencies. Results of a subgroup
analysis of graft patency in the PVAG patients that were
accessed less than 72 hours after implant demonstrate a
primary patency rate of 0.46, and this is not significantly
different when compared with the graft accessed after 72
hours (patency rate of 0.56; P = .6553). There was no
increase in infection rates of the PVAG graft with early
cannulation. Lohr et al6 demonstrated early access of the
DIASTAT graft not only decreased patency but also
increased infection rate of the access significantly.
Schuman7 reported that although early access of the
Perma-Seal graft occurred without complications, both
primary and secondary patencies were reduced when
compared with ePTFE. Perma-Seal grafts also had a
higher rate of infection compared with that of ePTFE
grafts.21
In this study, it is important to note that only 1 of 71
patients who received the PVAG graft underwent the
placement of a TVC at the time of surgery, whereas 9 of
71 patients who received the ePTFE graft underwent the
placement of a TVC at the time of surgery. Again, the
increasing number of patients who require urgent access is
exemplified in this study with more than 49 patients need-
ing urgent dialysis as noted with placement of TVCs
before or during the operation. Although early referral to
surgeons for early access placement has been the hallmark
of the DOQI guidelines, our data demonstrate that this is
not occurring. Early referral to the surgeons could possi-
bly reduce the high incidence of TVCs; however, the real-
ity is that today there is a dramatic need for a prosthetic
graft that can be cannulated early.
The total native vessel disease (both arterial and
venous components) complications (Table VII) observed
for the two study groups are thought to be related to non-
virginal prosthetic arm graft placement, preexisting fac-
tors, and an increase in the number of patients in the
PVAG group who had upper arm graft placements. The
multiple procedures for graft salvage in this group were
due to repeated angioplasty of the central veins, which
proved over time not to be a durable procedure. Also, the
incidence of plaque formation near the arterial anastomo-
sis regions of the graft was higher in the PVAG group than
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in the ePTFE group, and this led to an increase in inflow
procedures to maintain graft patency.
The only major technical complication that the PVAG
graft demonstrated over the ePTFE graft was kinking. The
PVAG graft after implantation is noted to have axial elon-
gation over time. This axial elongation can create kinking
if improper implantation technique is performed.
Technique for implantation must allow for the axial elon-
gation of the graft. If the implantation technique does not
allow for axial elongation, then kinking will occur at either
the apex of the loop or at the anastomosis, and this will
result in graft thrombosis. Several technical suggestions
are recommended to reduce the incidence of kinking.
These include a larger counterincision near the apex of the
loop portion of the graft with undermining to accommo-
date the elongation; a wider loop at the apex of a forearm
loop fistula to reduce angulation, with the use of a two-
sheathed method of implantation to also reduce the angu-
lation at the apex of the loop fistula; and finally, the
elimination of acute angles at both the arterial and venous
anastomoses to reduce the incidence of kinking at those
areas. Amano et al22 and Allen et al23 also experienced
kinking of PVAG grafts initially, but have since reported
that proper attention to the placement procedures for the
PVAG graft24 has minimized the kinking-related compli-
cations and long-term patencies are equal to that of
ePTFE grafts.18
The time to hemostasis with the PVAG was signifi-
cantly shorter as compared with the ePTFE control with
nearly half of all punctures taking 2 minutes or less to
reach hemostasis. There may be economic benefits as well
as favorable patient quality of life issues associated with
decreased dialysis treatment time with a graft with rapid
and consistent hemostasis times.
In summary, this study has demonstrated that the
PVAG graft has demonstrated similar patency and compli-
cation rates when compared with the ePTFE graft for use
as a dialysis graft. However, the PVAG graft has been
shown to be able to be cannulated early without increas-
ing infection within the graft or sacrificing patency.
Although early referral still remains a hallmark for decreas-
ing temporary catheter use, this graft, which allows early
access, may also reduce temporary catheter use in this
complex and medically demanding group of patients.
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DISCUSSION
Dr David L. Cull (Greenville, SC). The authors have pre-
sented results of a multicenter prospective randomized trial that
compares patency and complications of arteriovenous grafts uti-
lizing standard expanded PTFE with the self-sealing polyurethane
Vectra graft. The authors have shown that there is no significant
difference in the patency or complication rate between the Vectra
graft and PTFE graft except for a significantly increased incidence
of graft kinking in the Vectra graft group.
My first question of the authors relates to the problem with
kinking of the Vectra graft. Yours is not the first study to report
difficulties with kinking of this graft. Studies in Australia and
Japan have had similar problems. One author even suggests
sewing a cuff of PTFE on the end of the Vectra graft to prevent
kinking near the anastomosis. You also seemed to have problems
with kinking in the distal forearm at the bend of the graft. What
technique do you use when tunneling this graft and at the anas-
tomosis to prevent kinking and have any of these techniques been
shown to prevent these problems?
Finally, in your discussion you assert that the advantage of
this graft is that it can be cannulated earlier than PTFE. However,
you did not directly compare results of early cannulation of the
Vectra graft to PTFE. Your assertion is based on similar overall
short-term and long-term results obtained between the groups
despite half the Vectra grafts having undergone early cannulation.
To demonstrate superiority of the Vectra graft, we must know
what effect early cannulation has on short-term and long-term
outcomes of PTFE arteriovenous grafts.
In reviewing the literature I found that the answer to this
question is more elusive than I originally thought. Although I
have avoided cannulation of PTFE grafts for at least 2 weeks after
implantation, it appears to me that this concept of delaying can-
nulation originated 20 years ago when grafts were tunneled with
tunnelers much larger than the graft itself and from experience
extrapolated from bovine grafts. In fact, several studies have
shown that PTFE arteriovenous graft can be accessed early with-
out compromising short-term or long-term outcome.
Although your study has shown that the Vectra graft can be
safely accessed within 2 weeks without affecting outcome, have
we set up a straw man to compare it with? Should we reassess the
concept that PTFE grafts cannot be accessed early without affect-
ing short-term or long-term outcome? In short, do you believe
that either your study or historical experience with PTFE indi-
cates that early cannulation of the Vectra graft will outperform
that which can be achieved with the standard PTFE graft?
I appreciate the authors sending me their manuscript in a
timely fashion for my review, and I appreciate the Society’s invi-
tation for me to review this paper. 
Dr Marc Glickman. Thank you, David. A couple of issues
here. One is about kinking. Kinking is seen in two areas. One
is at the loop component of the graft, and one is at the anasto-
motic sites. As time evolved, we saw that there are ways and
methods to prevent or reduce kinking. Kinking is noted in our
study to occur or be observed within the first 60 to 80 days
after graft implantation. There are several methods for implant-
ing the graft that can reduce or avoid kinking. One is a method
that we designed that is a two-sheath method for implanting
the graft that would give a wider curve to the graft for elonga-
tion to occur. There also has to be a larger pocket in the loop
portion of the graft for the axial elongation to occur without
reducing or impinging on the graft itself. At the anastomotic
site, sharp angulation to either the artery or vein needs to be
reduced, and tension needs to be applied at the arterial or
venous anastomosis. I had the pleasure of going to Japan this
year where I looked over these data and came up with these rec-
ommendations to review or reduce the kinking episodes within
the graft.
With regard to early access of this graft compared with
PTFE, the study was not designed to compare the efficacy of
early accessing of ePTFE. The literature is complicated, as you
have noted. There are several articles. Haikim has noted there is
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no difference in accessing of PTFE grafts with both complica-
tion and patency rates, but there is no well-defined and well-
discussed study looking at early accessing of the PTFE graft. We
designed this study or looked at this study showing that
although there may not be superiority of the Vectra graft over
PTFE, I feel we have proven that the Vectra graft can be
accessed early without changing the complication rate or the
primary and secondary patency. To date, there has been no
study that has determined that a graft can be accessed early
without changing primary patency rates.
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